Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Icagen ends sickle cell drug trial
The decision followed a planned meeting with an independent Data Monitoring Committee which recommended that the trial of the sickle cell drug senicapoc be terminated because of the
The decision followed a planned meeting with an independent Data Monitoring Committee which recommended that the trial of the sickle cell drug senicapoc be terminated because of the
The trial is designed to test the efficacy of Ceflatonin in patients who have failed or were intolerant to treatment with prior tyrosine kinase inhibitors. CML patients routinely
The subpoena requested the production of documents and information relating to the proposed settlement of the Plavix patent litigation pending in the US. Bristol-Myers Squibb said it intends
The milestone was specifically connected to one of the several orally available biologics that are the focus of the collaboration. “We are pleased to have achieved this milestone
The study showed that 22 patients who received the immunotherapy had a median survival rate of 35 months. The company previously reported final median survival results from its
Guangzhou Pharmaceuticals Corporation (GP Corp.) has facilities located throughout Guangdong Province and southeast China. The deal has been made through Alliance BMP which was formed by Beijing Med-Pharm
Wyeth entered into an equity transfer agreement with Takeda in May 2003. Financial details of the equity transfer were not disclosed. “The full ownership of WKK is part
Viventia's lead product, Proxinium, is being developed to treat late stage, locally advanced head and neck cancer and is currently enrolling patients in a phase III global trial
The drug, AZD-103/ELND005, is currently being evaluated in multiple phase I clinical studies, and the companies anticipate starting phase II clinical studies around the end of 2007. Fast
In this clinical trial, Tovaxin therapy was shown to be safe and effective. The analysis showed that Tovaxin therapy achieved a 90% reduction in annualized relapse rate in